Trial Title: A Phase III Clinical Trial Comparing the Efficacy and Safety of Intravenous Injection of UB-851 and Eprex® in Hemodialysis Patients with Renal Anemia, Including an Extension Safety Assessment.
Trial Period: 20180801-20201231
Project Number: XMRPG8H0491
Trial Title: Research on the Development of a Chronic Kidney Disease Patient Blood Dialysis Needle Leakage Prevention and Real-time Monitoring System Using Smart Sensing Combined with Internet of Things (IoT) Technology.
Trial Period: From January 1, 2019, to December 31, 2019
Project Number: Chang Gung Medical Research Project
Trial Title: Tuberculosis High-Risk Population Prevention and Control Commissioned Research Project - Screening of Latent Tuberculosis Infection in Hemodialysis Patients.
Trial Period: 20180905-20190505
Project Number: None
Trial Title: Observational Database of Chronic Kidney Disease (CKDOD).
Trial Period: 20180601-20201231
Project Number: XMRPG8H0481
Trial Title: Treatable Rare Disease: Epidemiological Study of Fabry's Disease in Patients with Chronic Kidney Disease.
Trial Period: 20171213-20201212
Project Number: XPRPG8H0081
Trial Title: Association of Renal Size Measured by Renal Ultrasonography with Individual Diseases or Body Measurement Indices: Data Analysis from a Single Medical Center in Taiwan.
Trial Period: 20170920-20190920
Project Number: None
Trial Title: Single-group Trial of ALXN1210 for Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) who have not received Complement Inhibitors.
Trial Period: 20170601-20200531
Project Number: XPRPG8G0502
Trial Title: Tuberculosis High-Risk Population Prevention and Control Commissioned Research Project - Screening and Quick Treatment of Latent Tuberculosis Infection in Hemodialysis Patients.
Trial Period: 20170405-20180404
Project Number: GMRPG8F0081
Trial Title: 2017 Chronic Kidney Disease Health Promotion Agency Promotion Project.
Trial Period: 20170301-20171130
Project Number: PMRPG8G0151
Trial Title: 2018 Chronic Kidney Disease Health Promotion Agency Promotion Project.
Trial Period: 20180301-20181130
Ongoing projects：
1. CMRPG8L0571 (20210201-20220131)
To explore the pathophysiological implications of COX-2 regulating uromodulin in dehydrated kidney injury XPRPG8H0083 (20200901-20210831)
2. Treatable rare diseases: epidemiological study of Fabry's disease in chronic kidney patients
3. Sponsor firm Novartis: Conducting a phase III clinical trial with a multi-center approach. This study is randomized, double-blind, and placebo-controlled, involving parallel groups. Its aim is to assess the safety and effectiveness of LNP023 in individuals diagnosed with primary IgA nephropathy.
4. Sponsored by Novartis (Study CLNP023X2203 or CLNP023A2301 Cross-Over Extension): Administering a multicenter rollover extension initiative to examine the long-term safety and acceptability of open-label iptacopan among adult participants affected by primary IgA nephropathy. This extension program is for those who have already participated in either study CLNP023X2203 or CLNP023A2301 and successfully completed it.
5. Supported by Alexion: Conducting a Phase 2 study designed with double-blind characteristics. This study employs randomization and a placebo-controlled framework. Its purpose is to assess both the effectiveness and safety of Ravulizumab in adult individuals diagnosed with proliferative Lupus Nephritis (LN) or immunoglobulin A Nephropathy (IgAN).
6. Sponsored by ROCHE: Initiating a Phase III clinical trial across multiple centers. This trial incorporates a randomized, double-blind, and placebo-controlled design. The main objective of this study is to evaluate the efficacy and safety of RO7434656, an antisense inhibitor targeting complement factor B, in patients diagnosed with primary IgA nephropathy who are at a high risk of disease progression.
7. Sponsored by Chinook: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)